Coreline Soft (CEO Jin-guk Kim), a medical artificial intelligence (AI) specialized company, announced that it published a research paper utilizing the AI-based lung cancer screening solution ‘Aview LCS’ in the European Journal. This study proves the possibility that AI technology can be used as a ‘first reading’ tool in the lung cancer screening interpretation process, and heralds an innovative change in the medical AI field.
|
▲[Korean Today] Aview LCS example image (Photo = Coreline Soft) © Reporter Byun A-rong |
This paper was written using data from the 4ITLR, a European lung cancer screening project. The research results showed that Aview LCS accurately detects lung nodules based on lung CT images, and can be used as a primary interpretation tool beyond the existing secondary interpretation role. Up until now, AI has been mainly used as a secondary interpretation tool to supplement the results detected by radiologists in the lung cancer screening process.
Coreline Soft emphasized, “If AI is used as a primary interpretation tool, the AI can first classify lung CT images, significantly reducing the workload of medical staff and increasing the efficiency of early diagnosis and treatment of lung cancer.”
AIView LCS is currently being actively used in lung cancer screening pilot projects in major European countries such as Germany, France, and Italy, as well as in Korea. In particular, Germany, after successfully completing a pilot project in collaboration with CorelineSoft, has designated AI-based lung cancer screening as a national essential recommendation, setting a new standard for lung cancer screening.
“As European countries gradually introduce AI technology into their lung cancer screening programs, Aview’s market leadership is becoming more solid,” said a Coreline Soft official.
Lung cancer is known to be a disease that is difficult to detect early due to the lack of early symptoms. However, with the introduction of AI technologies such as Aview LCS, the accuracy of lung nodule detection is expected to improve, and the patient survival rate can be greatly increased through early diagnosis. Experts are paying attention to the possibility that AI will advance beyond the level of assisting medical staff and to the level of being able to operate independently in special fields such as lung cancer screening.
Based on these research results, CorelineSoft plans to further strengthen its position in the global medical AI market by leading the way in proving the potential of AI solutions in the field of lung cancer screening. The company stated that “AI-based lung cancer screening solutions will significantly improve medical accessibility and accuracy,” and expressed its ambition to expand the market to other continents outside of Europe in the future.
© The Korean Today – All Rights Reserved